ArticleHealth policy and technology2022
Overcoming the COVID-19 Pandemic in Indonesia: A Science, technology, and innovation (STI) policy perspective.
Article in Health policy and technology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Historical review of the Indonesian government's response to health crisis: From the Spanish flu to the COVID-19 pandemic.One health (Amsterdam, Netherlands) · 2025Article
- Association between cardiovascular diseases and COVID-19 pneumonia outcome in Indonesia: a multi-center cohort study.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scientific abstract: R&D serves as one of the imperative aspects in handling the COVID-19 pandemic. Since the Indonesian government has declared the COVID-19 pandemic as a national disaster, a number of accelerated regulations were stipulated, engaging research and innovation acknowledged as Science, technology, and innovation (STI) Policy. The results of the regulation mapping in Indonesia during 2020-2021 include the 9 regulations (categorized as STI Policy and dominated by institutional settings of 44.4%, operational mechanisms of 33.3%, and legal devices of 22.3%) as an attempt to address the COVID-19 pandemic. Hence, it is expected that the implementation of STI Policy plays a role in generating the 50 innovation products through the COVID-19 research and innovation consortium. Public interest abstract: The COVID-19 pandemic has been declared as a national disaster in Indonesia. There are nine regulations in the field of Science, technology, and innovation (STI) Policy set by the Indonesian government until July 2021, which regulate institutions, by institutionalizing the implementation of research and innovation in the health sector. The institution is acknowledged as the COVID-19 Research Consortium, consisting of government R&D institutions, universities, industrial R&D institutions, professional associations, regulators, industry, and 50 research and innovation products which have been launched by this consortium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.